Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03500666
Other study ID # BND and RND
Secondary ID
Status Recruiting
Phase N/A
First received April 2, 2018
Last updated April 15, 2018
Start date January 1, 2018
Est. completion date December 31, 2018

Study information

Verified date April 2018
Source Fujian Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objective to compare the advantages and disadvantages of robotic and conventional endoscopic thyroidectomy for thyroid cancer.


Description:

To compare the difference of operative time and complication between two operative methods in robot neck surgery and routine endoscopic surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 31, 2018
Est. primary completion date December 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. papillary thyroid carcinoma with clinically suspected or confirmed lateral lymph node metastasis;

2. patient's concerns of neck scars and cosmetic requirement.

The exclusion criteria were as follows:

1) tumor size >4cm; 2) previous neck surgical history; 3)residual or recurrent tumors; 4) suspicious primary tumor or metastatic lymph node invasion of major vascular structures or recurrent laryngeal nerve.

5)metastatic lymph nodes occurred below the sternoclavicular joint.

Study Design


Intervention

Device:
Robot
Robot lateral neck lymph node dissection
Total endoscopic
Total endoscopic lateral cervical lymph node dissection

Locations

Country Name City State
China Fujian Medical University Union Hospital FuZhou Fujian
China Wen-xin ZHAO Fuzhou Fujian

Sponsors (1)

Lead Sponsor Collaborator
Fujian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lateral cervical lymph node cleaning time Lateral cervical lymph node clean time from that beginning of cut the SCM leading edge to the end of the specimen During surgery
Primary Accessory nerve injury Accessory nerve injury During surgery
Primary Intraoperative internal jugular vein bleeding. Internal carotid vein hemorrhage affect that surgical procedure 6 months after surgery
Secondary The time of the thyroid gland removal The time of the thyroid gland removal , including the opening of the white line to the thyroid, and the end of the specimen During surgery
Secondary Number of participants with HypoParathyroidism The parathyroid function was examined six months after surgery. 6 months after surgery
Secondary Recurrent laryngeal nerve injury. The recurrent laryngeal nerve function due to nerve injury or thermal damage can not be recovered for 6 months. 6 months after surgery
See also
  Status Clinical Trial Phase
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn NCT01707056 - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma N/A
Completed NCT00215605 - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Phase 1
Completed NCT06439745 - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Terminated NCT04327999 - Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Phase 2
Completed NCT02194920 - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function N/A
Enrolling by invitation NCT06095362 - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW Phase 1
Not yet recruiting NCT05949424 - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Phase 4
Active, not recruiting NCT02145143 - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study N/A
Terminated NCT01865838 - A Study Into the Effect of Seprafilm in Open Total Thyroidectomy N/A
Recruiting NCT00749697 - Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases N/A
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed NCT01813136 - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Phase 2
Recruiting NCT05668962 - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Phase 2
Active, not recruiting NCT02185560 - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Completed NCT04462471 - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Phase 1
Completed NCT01433809 - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm N/A
Recruiting NCT00929318 - Influence of Thyroid Hormones on the Woundhealing Process N/A
Completed NCT05178186 - Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer N/A
Completed NCT02773667 - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine